SGLT2 inhibitors demonstrate robust benefits for heart failure and cardiovascular mortality across large CVOTs, with parallel reductions in IL-6, TNF-α, and oxidative stress that may translate to stroke and dementia risk reduction. This evidence concerns the gene IL6 and Stroke.